

Supplementary Information

Supplemental References

82. Zara G, Ermani M, Rondinone R, Arienti S, and Doria A, Thalidomide and sensory neurotoxicity: a neurophysiological study. *Journal of Neurology, Neurosurgery & Psychiatry*, 2008. **79**(11): 1258.
83. Argyriou AA, Polychronopoulos P, Iconomou G, *et al.*, Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. *Acta Oncol*, 2007. **46**(8): 1131-7.
84. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, and Krarup C, Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. *Brain*, 2007. **130**(4): 1076-1088.
85. Park SB, Lin CS, Krishnan AV, *et al.*, Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. *Brain*, 2009. **132**(Pt 10): 2712-23.
86. Moldovan M, Alvarez S, and Krarup C, Motor axon excitability during Wallerian degeneration. *Brain*, 2009. **132**(Pt 2): 511-23.
87. Park SB, Lin CS, Krishnan AV, *et al.*, Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. *Muscle Nerve*, 2011. **43**(3): 367-74.
88. Nasu S, Misawa S, Nakaseko C, *et al.*, Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy. *Clin Neurophysiol*, 2014. **125**(2): 381-7.
89. Meregalli C, Bonomo R, Cavaletti G, and Carozzi VA, Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice. *Neurosci Lett*, 2021. **749**: 135739.
90. Mariotto S, Carta S, Bozzetti S, *et al.*, Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels. *J Neurol*, 2020. **267**(10): 2881-2887.
91. Benashley LW, Bucy AM, Wertheim BC, *et al.*, Paclitaxel Treatment Effects on Neurofilament Light Chain (NF-L), a Possible Biomarker of Chemotherapy-Induced Peripheral Neuropathy (CIPN). *Cancer Epidemiol Biomarkers Prev*, 2022. **31**(7): 1510-1511.
92. Huehnchen P, Bangemann N, Lischewski S, *et al.*, Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial - Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial. *Front Med (Lausanne)*, 2022. **9**: 967964.
93. Karteri S, Bruna J, Argyriou AA, *et al.*, Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. *J Peripher Nerv Syst*, 2022. **27**(2): 166-174.
94. Mortensen C, Steffensen KD, Simonsen E, *et al.* Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in ovarian cancer patients. *Pain*, 2022.
95. Kim S, Kim KH, Hyun J, *et al.* Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. *Fron Oncol* 2022, 12:942960.
96. Velasco R, Argyriou AA, Marco C, *et al.* Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity. *J Neurol*. 2022
97. Kim SH, Choi MK, Park NY, *et al.*, Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. *Sci Rep*, 2020. **10**(1): 7995.
98. Sumitani M, Ogata T, Natori A, *et al.*, Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy. *Biomed Rep*, 2016. **4**(6): 758-760.
99. Geisler S, Huang SX, Strickland A, *et al.*, Gene therapy targeting SARM1 blocks pathological axon degeneration in mice. *J Exp Med*, 2019. **216**(2): 294-303.

100. Gould SA, Gilley J, Ling K, Jafar-Nejad P, Rigo F, Coleman M. *Sarm1* haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration. *Cell Rep*, 2021. **37**(11):110108
101. Ico JD, Thompson PR. The chemical biology of NAD⁺ regulation in axon degeneration. *Curr Opin Chem Biol*, 2022. **69**:102176.
102. Feldman HC, Merlini E, Guijas C, et al. Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain. *PNAS*, 2022.**119**(35): e2208457119.
103. Li WH, Huang K, Cai Y, et al. Permeant fluorescent probes visualize the activation of SARM1 and uncover an anti-neurodegenerative drug candidate. *eLife*, 2021. **10**:e67381.
104. Bratkowski M, Burdett TC, Danao J, et al. Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease. *Neuron*, 2022. **111**(22):3711-3726.
105. Hughes RO, Bosanac T, Mao X, et al., Small Molecule SARM1 Inhibitors Recapitulate the SARM1(-/-) Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate. *Cell Rep*, 2021. **34**(1): 108588.
106. Snavely AR, Heo K, Petrova V, et al. Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion. *Dis Model Mech*, 2022. **15**(12):dmm049358.
107. Bruna J, Videla S, Argyriou AA, et al., Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. *Neurotherapeutics*, 2018. **15**(1): 178-189.

Complete Reference List for Table 1

1. Turkiew E, Falconer D, Reed N, and Höke A, Deletion of *Sarm1* gene is neuroprotective in two models of peripheral neuropathy. *J Peripher Nerv Syst*, 2017. **22**(3): 162-171.
2. Bosanac T, Hughes RO, Engber T, et al., Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy. *Brain*, 2021. **144**(10): 3226-3238.
3. Li Y, Pazyra-Murphy MF, Avizonis D, et al., Sarm1 activation produces cADPR to increase intra-axonal Ca⁺⁺ and promote axon degeneration in PIPN. *J Cell Biol*, 2022. **221**(2).
4. Geisler S, Doan RA, Strickland A, et al., Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. *Brain*, 2016. **139**(Pt 12): 3092-3108.
5. Essuman K, Summers DW, Sasaki Y, et al., The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD(+) Cleavage Activity that Promotes Pathological Axonal Degeneration. *Neuron*, 2017. **93**(6): 1334-1343.e5.

6. Geisler S, Doan RA, Cheng GC, *et al.*, Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. *JCI Insight*, 2019. **4**(17).
7. Gerdtts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. *J Neurosci*, 2013. **33**(33):13569-80.
8. Gould SA, White M, Wilbrey AL, *et al.*, Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1(-/-) mice. *Exp Neurol*, 2021. **338**: 113607.
9. Snavely AR, Heo K, Petrova V, *et al.* Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion. *Dis Model Mech*, 2022. **15**(12):dmm049358.
10. Cetinkaya-Fisgin A, Luan X, Reed N, *et al.*, Cisplatin induced neurotoxicity is mediated by Sarm1 and calpain activation. *Sci Rep*, 2020. **10**(1): 21889.
11. Tian W, Czopka T, and López-Schier H, Systemic loss of Sarm1 protects Schwann cells from chemotoxicity by delaying axon degeneration. *Commun Biol*, 2020. **3**(1): 49.

Complete Reference List for Table 2

1. Roelofs RI, Hrushesky W, Rogin J, and Rosenberg L, Peripheral sensory neuropathy and cisplatin chemotherapy. *Neurology*, 1984. **34**(7): 934-934.
2. Pagès M, Pagès AM, and Bories-Azeau L, Severe sensorimotor neuropathy after cisplatin therapy. *J Neurol Neurosurg Psychiatry*, 1986. **49**(3): 333-4.
3. Gastaut JL and Pellissier JF, [Neuropathy caused by cisplatin. Clinical, electrophysiological and morphological study]. *Rev Neurol (Paris)*, 1985. **141**(10): 614-26.
4. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, *et al.*, Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. *Brain*, 1993. **116** (Pt 5): 1017-41.
5. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, and Krarup C, Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. *Brain*, 2007. **130**(4): 1076-1088.

6. Wiernik PH, Schwartz EL, Strauman JJ, *et al.*, Phase I Clinical and Pharmacokinetic Study of Taxol1. *Cancer Research*, 1987. **47**(9): 2486-2493.
7. van den Bent MJ, van Raaij-van den Aarssen VJM, Verweij J, Doorn PAV, and Sillevs Smitt PAE, Progression of paclitaxel-induced neuropathy following discontinuation of treatment. *Muscle & Nerve*, 1997. **20**(6): 750-752.
8. Sahenk Z, Barohn R, New P, and Mendell JR, Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. *Arch Neurol*, 1994. **51**(7): 726-9.
9. Fazio R, Quattrini A, Bolognesi A, *et al.*, Docetaxel neuropathy: a distal axonopathy. *Acta Neuropathol*, 1999. **98**(6): 651-3.
10. New PZ, Jackson CE, Rinaldi D, Burris H, and Barohn RJ, Peripheral neuropathy secondary to docetaxel (Taxotere). *Neurology*, 1996. **46**(1): 108-11.
11. Pero ME, Meregalli C, Qu X, *et al.*, Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy. *Proc Natl Acad Sci U S A*, 2021. **118**(4).
12. Santilli A and Martinez-Thompson J, An Atypical Presentation of Bortezomib-Induced Peripheral Neuropathy (1625). *Neurology*, 2021. **96**(15 Supplement): 1625.
13. Thawani SP, Tanji K, De Sousa EA, Weimer LH, and Brannagan TH, 3rd, Bortezomib-associated demyelinating neuropathy--clinical and pathologic features. *J Clin Neuromuscul Dis*, 2015. **16**(4): 202-9.
14. Bradley WG, Lassman LP, Pearce GW, and Walton JN, The neuromyopathy of vincristine in man: Clinical, electrophysiological and pathological studies. *Journal of the Neurological Sciences*, 1970. **10**(2): 107-131.
15. Gottschalk PG, Dyck PJ, and Kiely JM, Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. *Neurology*, 1968. **18**(9): 875-82.
16. McLeod JG and Penny R, Vincristine neuropathy: an electrophysiological and histological study. *J Neurol Neurosurg Psychiatry*, 1969. **32**(4): 297-304.
17. Mores GR, D'Agostino AN, and Jarcho LW, Neuropathy in Lymphoblastic Leukemia Treated With Vincristine. *Archives of Neurology*, 1967. **16**(4): 377-384.
18. Chaudhry V, Cornblath DR, Corse A, *et al.*, Thalidomide-induced neuropathy. *Neurology*, 2002. **59**(12): 1872-5.
19. Fullerton PM and O'Sullivan DJ, Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. *J Neurol Neurosurg Psychiatry*, 1968. **31**(6): 543-51.
20. Corbin ZA, Nguyen-Lin A, Li S, *et al.*, Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. *J Neurooncol*, 2017. **132**(3): 439-446.
21. Mariotto S, Ferrari S, Sorio M, *et al.*, Brentuximab vedotin: axonal microtubule's Apollyon. *Blood Cancer J*, 2015. **5**(8): e343.